Trial · NCT01537549
Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy
NCT01537549, Phase 1, Phase 2, Completed, Weill Medical College of Cornell University; results first posted 2017-04-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy. Trials, record NCT01537549. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01537549
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy
- NCT number
- NCT01537549
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 11 participants, actual
- Lead sponsor
- Weill Medical College of Cornell University
- Conditions
- Progressive Supranuclear Palsy
- Interventions
- alpha-lipoic acid and L-acetyl carnitine
- First posted
- 2012-02-23
- Last updated
- 2017-05-30
- Results first posted
- 2017-04-12
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Adverse Events | at 25 weeks | Incidence and severity of adverse events |
| Secondary | Cerebral Oxidative Stress Markers | at baseline and at week 5 | changes of cerebral lactate and glutathione levels as determined by magnetic resonance spectroscopy |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Adverse Events | at 25 weeks | ITT | Number of Adverse Events | NUMBER |
| SECONDARY | Cerebral Oxidative Stress Markers | at baseline and at week 5 | per Protocol | Ratio | MEAN |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Adverse Events | Juvenon | 23 | Number of Adverse Events | ||
| Cerebral Oxidative Stress Markers | Juvenon at Baseline | 4 | Standard Deviation 1.67 | Ratio | |
| Cerebral Oxidative Stress Markers | Juvenon at 1 Month | 4.6 | Standard Deviation 1.41 | Ratio |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Juvenon | 11 | |
| Overall Study | COMPLETED | Juvenon | 8 | |
| Overall Study | NOT COMPLETED | Juvenon | 3 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Gastro Disturbances | Gastrointestinal disorders | Juvenon | 5 | 11 | 7 |
| other | Odor of Urine, Breath, or Sweat | General disorders | Juvenon | 4 | 11 | 5 |
| other | Skin Rashes, Itching, Swelling | Skin and subcutaneous tissue disorders | Juvenon | 2 | 11 | 3 |
| other | Bronchoconstriction, Cough | Respiratory, thoracic and mediastinal disorders | Juvenon | 1 | 11 | 1 |
| other | Other Possible Effects | General disorders | Juvenon | 6 | 11 | 9 |
| serious | Leg Cellulitis | Infections and infestations | Juvenon | 1 | 11 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Juvenon | ||
| Total, other adverse events | Juvenon | 9 | 11 |
| Total, serious adverse events | Juvenon | 1 | 11 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01537549
GET https://conductscience.org/api/trials/v1/NCT01537549/registered